Do analysts prefer NUWE or DYNT?

Given Dynatronics' higher probable upside, analysts plainly believe Dynatronics is more favorable than Nuwellis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dynatronics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, NUWE or DYNT?

Dynatronics has higher revenue and earnings than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuwellis $8.77M 0.02 -$17.52M -$2.24 thousand N/A Dynatronics $33.60M 0.00 -$2.70M -$1.35 N/A

Is NUWE or DYNT more profitable?

Dynatronics has a net margin of -8.35% compared to Nuwellis' net margin of -214.90%. Dynatronics' return on equity of -41.81% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -214.90% -32,351.83% -249.08% Dynatronics -8.35% -41.81% -9.56%

Do analysts prefer BIOL or NUWE?

Given BIOLASE's higher possible upside, equities analysts clearly believe BIOLASE is more favorable than Nuwellis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BIOLASE 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, BIOL or NUWE?

Nuwellis has lower revenue, but higher earnings than BIOLASE. Nuwellis is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BIOLASE $48.83M 0.00 -$20.63M -$14.94 N/A Nuwellis $8.77M 0.02 -$17.52M -$2.24 thousand N/A

Is BIOL or NUWE more profitable?

BIOLASE has a net margin of -41.65% compared to Nuwellis' net margin of -214.90%. BIOLASE's return on equity of -1,782.73% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets BIOLASE -41.65% -1,782.73% -55.31% Nuwellis -214.90% -32,351.83% -249.08%

Do analysts prefer NUWE or VERO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Venus Concept 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, NUWE or VERO?

Nuwellis has higher earnings, but lower revenue than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuwellis $8.77M 0.02 -$17.52M -$2.24 thousand N/A Venus Concept $58.88M 0.01 -$47M -$48.84 N/A

Is NUWE or VERO more profitable?

Venus Concept has a net margin of -92.76% compared to Nuwellis' net margin of -214.90%. Venus Concept's return on equity of -1,904.25% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -214.90% -32,351.83% -249.08% Venus Concept -92.76% -1,904.25% -85.22%

Do analysts rate NUWE or XAGE?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Longevity Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is NUWE or XAGE more profitable?

Nuwellis has a net margin of -214.90% compared to Longevity Health's net margin of -682.67%. Longevity Health's return on equity of 0.00% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -214.90% -32,351.83% -249.08% Longevity Health -682.67% N/A -261.90%

Do analysts prefer NUWE or PFSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, NUWE or PFSA?

Nuwellis has higher revenue and earnings than Profusa. Nuwellis is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuwellis $8.77M 0.02 -$17.52M -$2.24 thousand N/A Profusa N/A N/A -$35.82M -$4.24 thousand N/A

Is NUWE or PFSA more profitable?

Profusa has a net margin of 0.00% compared to Nuwellis' net margin of -214.90%. Profusa's return on equity of 0.00% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -214.90% -32,351.83% -249.08% Profusa N/A N/A -1,348.07%

Nuwellis (NUWE) Competitors

$2.05 -0.15 (-6.82%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$1.86 -0.19 (-9.02%)

As of 07/24/2026 07:34 PM Eastern

Compare

NUWE vs. DYNT, BIOL, VERO, XAGE, and PFSA

Should you buy Nuwellis stock or one of its competitors? MarketBeat compares Nuwellis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuwellis include Dynatronics (DYNT), BIOLASE (BIOL), Venus Concept (VERO), Longevity Health (XAGE), and Profusa (PFSA). These companies are all part of the "medical equipment" industry.

How does Nuwellis compare to Dynatronics?

Nuwellis (NASDAQ:NUWE) and Dynatronics (NASDAQ:DYNT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Dynatronics has a net margin of -8.35% compared to Nuwellis' net margin of -214.90%. Dynatronics' return on equity of -41.81% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-214.90%	-32,351.83%	-249.08%
Dynatronics	-8.35%	-41.81%	-9.56%

Nuwellis has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Dynatronics has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

Given Dynatronics' higher probable upside, analysts plainly believe Dynatronics is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dynatronics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Nuwellis had 1 more articles in the media than Dynatronics. MarketBeat recorded 1 mentions for Nuwellis and 0 mentions for Dynatronics. Nuwellis' average media sentiment score of 0.94 beat Dynatronics' score of 0.00 indicating that Nuwellis is being referred to more favorably in the media.

Company	Overall Sentiment
Nuwellis	Positive
Dynatronics	Neutral

3.1% of Nuwellis shares are owned by institutional investors. Comparatively, 4.2% of Dynatronics shares are owned by institutional investors. 1.6% of Nuwellis shares are owned by insiders. Comparatively, 2.9% of Dynatronics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Dynatronics has higher revenue and earnings than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.77M	0.02	-$17.52M	-$2.24 thousand	N/A
Dynatronics	$33.60M	0.00	-$2.70M	-$1.35	N/A

Summary

Dynatronics beats Nuwellis on 10 of the 14 factors compared between the two stocks.

How does Nuwellis compare to BIOLASE?

BIOLASE (NASDAQ:BIOL) and Nuwellis (NASDAQ:NUWE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

In the previous week, BIOLASE and BIOLASE both had 1 articles in the media. Nuwellis' average media sentiment score of 0.94 beat BIOLASE's score of 0.73 indicating that Nuwellis is being referred to more favorably in the news media.

Company	Overall Sentiment
BIOLASE	Positive
Nuwellis	Positive

8.8% of BIOLASE shares are held by institutional investors. Comparatively, 3.1% of Nuwellis shares are held by institutional investors. 0.3% of BIOLASE shares are held by insiders. Comparatively, 1.6% of Nuwellis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

BIOLASE has a net margin of -41.65% compared to Nuwellis' net margin of -214.90%. BIOLASE's return on equity of -1,782.73% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BIOLASE	-41.65%	-1,782.73%	-55.31%
Nuwellis	-214.90%	-32,351.83%	-249.08%

Given BIOLASE's higher possible upside, equities analysts clearly believe BIOLASE is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BIOLASE	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nuwellis has lower revenue, but higher earnings than BIOLASE. Nuwellis is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BIOLASE	$48.83M	0.00	-$20.63M	-$14.94	N/A
Nuwellis	$8.77M	0.02	-$17.52M	-$2.24 thousand	N/A

BIOLASE has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Nuwellis has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market.

Summary

BIOLASE beats Nuwellis on 9 of the 13 factors compared between the two stocks.

How does Nuwellis compare to Venus Concept?

Nuwellis (NASDAQ:NUWE) and Venus Concept (NASDAQ:VERO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Nuwellis has higher earnings, but lower revenue than Venus Concept. Venus Concept is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.77M	0.02	-$17.52M	-$2.24 thousand	N/A
Venus Concept	$58.88M	0.01	-$47M	-$48.84	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Venus Concept	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Nuwellis had 1 more articles in the media than Venus Concept. MarketBeat recorded 1 mentions for Nuwellis and 0 mentions for Venus Concept. Nuwellis' average media sentiment score of 0.94 beat Venus Concept's score of 0.00 indicating that Nuwellis is being referred to more favorably in the media.

Company	Overall Sentiment
Nuwellis	Positive
Venus Concept	Neutral

Nuwellis has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market. Comparatively, Venus Concept has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market.

3.1% of Nuwellis shares are owned by institutional investors. Comparatively, 87.4% of Venus Concept shares are owned by institutional investors. 1.6% of Nuwellis shares are owned by company insiders. Comparatively, 28.0% of Venus Concept shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Venus Concept has a net margin of -92.76% compared to Nuwellis' net margin of -214.90%. Venus Concept's return on equity of -1,904.25% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-214.90%	-32,351.83%	-249.08%
Venus Concept	-92.76%	-1,904.25%	-85.22%

Summary

Venus Concept beats Nuwellis on 7 of the 13 factors compared between the two stocks.

How does Nuwellis compare to Longevity Health?

Nuwellis (NASDAQ:NUWE) and Longevity Health (NASDAQ:XAGE) are both small-cap medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

Nuwellis has a net margin of -214.90% compared to Longevity Health's net margin of -682.67%. Longevity Health's return on equity of 0.00% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-214.90%	-32,351.83%	-249.08%
Longevity Health	-682.67%	N/A	-261.90%

In the previous week, Nuwellis had 1 more articles in the media than Longevity Health. MarketBeat recorded 1 mentions for Nuwellis and 0 mentions for Longevity Health. Nuwellis' average media sentiment score of 0.94 beat Longevity Health's score of 0.67 indicating that Nuwellis is being referred to more favorably in the media.

Company	Overall Sentiment
Nuwellis	Positive
Longevity Health	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Longevity Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Nuwellis has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, Longevity Health has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

Longevity Health has lower revenue, but higher earnings than Nuwellis. Longevity Health is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.77M	0.02	-$17.52M	-$2.24 thousand	N/A
Longevity Health	$1.05M	0.36	-$10.37M	-$4.29	N/A

3.1% of Nuwellis shares are held by institutional investors. Comparatively, 24.2% of Longevity Health shares are held by institutional investors. 1.6% of Nuwellis shares are held by insiders. Comparatively, 29.0% of Longevity Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Nuwellis and Longevity Health tied by winning 7 of the 14 factors compared between the two stocks.

How does Nuwellis compare to Profusa?

Nuwellis (NASDAQ:NUWE) and Profusa (NASDAQ:PFSA) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

Nuwellis has higher revenue and earnings than Profusa. Nuwellis is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.77M	0.02	-$17.52M	-$2.24 thousand	N/A
Profusa	N/A	N/A	-$35.82M	-$4.24 thousand	N/A

Nuwellis has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, Profusa has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Profusa has a net margin of 0.00% compared to Nuwellis' net margin of -214.90%. Profusa's return on equity of 0.00% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-214.90%	-32,351.83%	-249.08%
Profusa	N/A	N/A	-1,348.07%

In the previous week, Profusa had 2 more articles in the media than Nuwellis. MarketBeat recorded 3 mentions for Profusa and 1 mentions for Nuwellis. Profusa's average media sentiment score of 1.43 beat Nuwellis' score of 0.94 indicating that Profusa is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuwellis	Positive
Profusa	Positive

3.1% of Nuwellis shares are owned by institutional investors. Comparatively, 9.8% of Profusa shares are owned by institutional investors. 1.6% of Nuwellis shares are owned by company insiders. Comparatively, 0.8% of Profusa shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Profusa beats Nuwellis on 7 of the 12 factors compared between the two stocks.

Get Nuwellis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUWE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NUWE vs. The Competition

Export

Metric	Nuwellis	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$157K	$7.29B	$6.87B	$12.26B
Dividend Yield	N/A	1.33%	2.67%	9.79%
P/E Ratio	0.00	48.63	27.14	23.64
Price / Sales	0.02	96.87	517.06	88.99
Price / Cash	N/A	25.71	50.54	59.64
Price / Book	0.04	6.73	10.28	6.07
Net Income	-$17.52M	$162.27M	$3.60B	$331.99M
7 Day Performance	-28.07%	-5.05%	-1.27%	-0.63%
1 Month Performance	-38.09%	-5.86%	-0.37%	-2.00%
1 Year Performance	-99.52%	-2.88%	18.30%	13.62%

Nuwellis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
NUWE Nuwellis	0.3289 of 5 stars	$2.05 -6.8%	N/A	-99.5%	$157K	$8.77M	N/A	70
DYNT Dynatronics	N/A	N/A	N/A	N/A	$653K	$33.60M	N/A	200
BIOL BIOLASE	N/A	N/A	N/A	N/A	$581K	$48.83M	N/A	160
VERO Venus Concept	0.1005 of 5 stars	$0.31 flat	N/A	N/A	$442K	$58.88M	N/A	410
XAGE Longevity Health	N/A	$0.21 flat	N/A	-94.8%	$376K	$1.05M	N/A	14

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NUWE) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuwellis (NUWE) Competitors

NUWE vs. DYNT, BIOL, VERO, XAGE, and PFSA

How does Nuwellis compare to Dynatronics?

Summary

How does Nuwellis compare to BIOLASE?

Summary

How does Nuwellis compare to Venus Concept?

Summary

How does Nuwellis compare to Longevity Health?

Summary

How does Nuwellis compare to Profusa?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUWE vs. The Competition

Nuwellis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuwellis (NUWE) Competitors

NUWE vs. DYNT, BIOL, VERO, XAGE, and PFSA

How does Nuwellis compare to Dynatronics?

Is NUWE or DYNT more profitable?

Which has more volatility and risk, NUWE or DYNT?

Do analysts prefer NUWE or DYNT?

Does the media favor NUWE or DYNT?

Do institutionals & insiders have more ownership in NUWE or DYNT?

Which has preferable valuation and earnings, NUWE or DYNT?

Summary

How does Nuwellis compare to BIOLASE?

Does the media refer more to BIOL or NUWE?

Do institutionals and insiders believe in BIOL or NUWE?

Is BIOL or NUWE more profitable?

Do analysts prefer BIOL or NUWE?

Which has higher earnings & valuation, BIOL or NUWE?

Which has more volatility & risk, BIOL or NUWE?

Summary

How does Nuwellis compare to Venus Concept?

Which has stronger earnings and valuation, NUWE or VERO?

Do analysts prefer NUWE or VERO?

Does the media prefer NUWE or VERO?

Which has more risk and volatility, NUWE or VERO?

Do insiders and institutionals hold more shares of NUWE or VERO?

Is NUWE or VERO more profitable?

Summary

How does Nuwellis compare to Longevity Health?

Is NUWE or XAGE more profitable?

Does the media prefer NUWE or XAGE?

Do analysts rate NUWE or XAGE?

Which has more volatility & risk, NUWE or XAGE?

Which has stronger valuation & earnings, NUWE or XAGE?

Do institutionals & insiders hold more shares of NUWE or XAGE?

Summary

How does Nuwellis compare to Profusa?

Which has stronger earnings & valuation, NUWE or PFSA?

Which has more volatility & risk, NUWE or PFSA?

Do analysts prefer NUWE or PFSA?

Is NUWE or PFSA more profitable?

Does the media prefer NUWE or PFSA?

Do institutionals and insiders believe in NUWE or PFSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUWE vs. The Competition

Nuwellis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools